EUCTR2010-018333-21-IT进行中（未招募）不适用
Receptorial radiotherapy with 177Lu-DOTA-Tyr3-Octreotate as Maintaining Therapy in Extended Small Cell Lung Cancer (SCLC) after a first standard chemotherapy line - IRST162.02
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1 Cytologic or hystologic diagnosis of Small Cell Lung Cancer (SCLC) 2 Performance Score < 2 (see Appendix A) 3 Age > 18 and < 75 years 4 Life expectancy of greater than 6 months 5 Extended stage of SCLC 6 Patient pre-treated with standard 1 st line chemotherapy: CDDP 75 mg/mq Day 1 or Carboplatin 300 mg/mq Day 1 or Carboplatin AUC 5 Day 1 and VP-16 100 mg/mq Days 1-3 every 21 days. 7 Patient with SD, PR or CR after a first line CT 8 Positive Octreoscan or PET/CT 68Ga-DOTANOC (cut/off > 1:1 from tumor and liver) or Positive stain of Somatostatin Receptor type 2 at the paraffin inclusions (histological revision will be centralized. Patients will be enrolled based on the local histological diagnosis) 9 Presence of at least of one measurable lesion in agreement to RECIST criteria 10 Patients must have normal organ and marrow function as defined below: - leukocytes >3,000/L - absolute neutrophil count >1,500/L - platelets >100,000/L - total bilirubin < 1.5 X institutional upper normal limits - AST(SGOT)/ALT(SGPT) <2.5 X institutional upper normal limits - Serum creatinine < 1.25 xULN (except in case of creatinine > 1.25 x ULN and ≤ 1.5 x ULN if creatinine clearance is > 60 ml/min) 11 Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. 12 Ability to understand and the willingness to sign a written informed consent document. 13 Geographic accessibility
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1 Uncontrolled intercurrent illness including: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements 2 Concomitant chemo-radiotherapic treatment 3 Previous diagnosis of tumor in the last 5 years, excluded non-melanoma skin cancer, carcinoma in situ of the cervix 4 Participation in another clinical trial with any investigational agents within 30 days prior to study screening 5 Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; women in lactation period must be escluded;
研究者
相似试验
进行中（未招募）
不适用
Receptorial radiotherapy with 177Lu DOTATATE in somatostatine receptors positive tumours, a phase II study.cancer patientsMedDRA version: 14.1Level: HLGTClassification code 10014713Term: Endocrine neoplasms malignant and unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002891-18-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
进行中（未招募）
不适用
Receptor radionuclide therapy with [177Lu-DOTA]0,Tyr3-octreotate (177Lu-DOTATATE): a phase II trial. - NDcancer patientsMedDRA version: 9.1Level: LLTClassification code 10028980Term: NeoplasmEUCTR2007-005517-20-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
招募中
1 期
Therapy with radiopharmaceutical 177Lu-DOTATOC (177Lu-edotreotide or 177Lu-octreotide) in patients with diagnosis of somatostatin receptor positive tumor: a multicenter, prospective phase 2 studyPatients must have histologically or cytologically confirmation of neuroendocrine tumors or any other tumor histotype documented as sst-positiveMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2023-000086-14-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS268
招募中
1 期
Radioimmunotherapy with 177Lu-DOTA-RITUXIMAB in B-cell lymphomaIRCT20210612051548N4Boushehr University of Medical Sciences10
进行中（未招募）
不适用
Radiometabolic treatment with 90Y-DOTA0-Tyr3]-octreotide (90Y-DOTATOC) or[90Y-DOTA0-Tyr3-Thr8]-octreotate (90Y-DOTATATE)in tumours expressing somatostatin receptorsPatient with tumour expressing somatostatine receptorsMedDRA version: 14.1Level: HLGTClassification code 10014713Term: Endocrine neoplasms malignant and unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003155-11-ITAZ. USL DI CESENA